XBiotech
Share
XBiotech is a fully integrated biopharmaceutical that uses proprietary technology to create True Human™ monoclonal antibody medicines.
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug
05/01/2026
From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy
From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy | XBiotech XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.
11/14/2023
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis | XBiotech (Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.
Click here to claim your Sponsored Listing.
Category
Website
Address
5217 Winnebago Lane
Austin, TX
78744
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |